key: cord-0875157-73x0jqu1
authors: Chopra, Arvind; Srikanth, Narayanam; Patwardhan, Bhushan
title: Withania somnifera as a Safer Option to Hydroxychloroquine in the Chemoprophylaxis of COVID-19: Results of Interim Analysis
date: 2021-08-18
journal: Complement Ther Med
DOI: 10.1016/j.ctim.2021.102768
sha: 98df6bd70ce9648edc167b9ae744a5ad29817342
doc_id: 875157
cord_uid: 73x0jqu1

OBJECTIVES: To study the efficacy and safety of Withania somnifera (WS) in the prophylaxis against COVID-19 in high risk health care workers (HCW) in comparison to hydroxychloroquine (HCQ). To evaluate general physical and mental health benefits of Ashwagandha. METHODS: A 16 week randomized prospective, open label, parallel efficacy, two arm multi-centre study. The primary efficacy measure is ‘failure of prophylaxis’ as confirmed COVID-19 by quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) at any time during the study period. This study on 400 participants from three centres is designed to establish non-inferiority for WS to HCQ for prophylaxis against COVID-19 at 80% power and significance P < 0.025, one sided. The interim analysis was carried out on 160 participants after completion of 8 weeks. RESULTS: Participants in both the arms were well matched at the baseline characteristics. 40 participants in the HCQ group and 26 participants in the WS group reported mild AE. The symptoms of confirmed COVID-19 were found to be 3.7% (95% CI 1.3 to 10.5%) in the HCQ and 1.3% (95% CI 0.02 to 6.7%) in the WS arm amongst the first 160 participants completing 8 weeks. CONCLUSION: Our intent was to explore a safer option to HCQ. We report that WS was not found inferior to HCQ and its efficacy was within the 15% non-inferiority margin set a-priori. WS as immunomodulator has other clinical benefits including reducing mental stress. Final report of this study is expected by end of August 2021. TRIAL REGISTRATION: CTRI/2020/08/027163 [Registered on: 14/08/2020].

A large number of health care workforce (HCW) is engaged in combatting COVID-19 have fallen prey to the virus. This is despite extensive use of personal protection equipment, strict personal discipline and other preventive measures such as social distancing, use of face mask, handwashing, and use of drugs like HCQ as prophylactic agents. Chemoprophylaxis against SARS-CoV-2 is needed, however there are no proven drugs yet. This study was initiated when vaccines were not available in India. Earlier studies have shown that HCQ was unable to prevent SARS-CoV-2 infection among hospital-based health care workers (HCW). 1 Concerns over misguided use of HCQ have been raised. 2 Despite insufficient evidence the J o u r n a l P r e -p r o o f HCQ. As a result, thousands of high-risk HCW consumed HCQ for a prolonged period. India has a legal system to recognize a practice of traditional, complementary and integrative medicine including Ayurveda, Yoga, Unani, Siddha, Homoeopathy (AYUSH). Based on available literature and empirical evidence, the Ministry of AYUSH has recommended Withania somnifera (WS) also known as Ashwagandha for COVID-19 prophylaxis 4 . The long-term safety of Ashwagandha is well documented 5, 6, 7 . WS as immunomodulator has other clinical benefits including reducing mental stress. 8 In previous studies selective-Th-1 upregulating activity of WS was demonstrated in mouse models 9 , which seems relevant in the management of COVID-19. Available data indicate that WS may be a good candidate for clinical repurposing in COVID-19 management. 10 Against this background that the current study was undertaken to explore use of WS as a safer prophylactic option to HCQ in COVID-19.

A randomized, open label, parallel efficacy, non-inferiority, two arm, multicentre, 16-week duration clinical trial was initiated in Sept 2020 to compare WS to HCQ for pre-exposure chemoprophylaxis. The trial protocol was approved by respective institutional ethics committees and was registered on August 14, 2020 at the Clinical Trial Registry -India 11 . 400 eligible participants from three centres (Mumbai, Hasan and Nagpur) were enrolled after the informed consent. The participants were randomized in two arms to receive 2 tablets of 250 mg standardized extract of WS twice daily or 400 mg HCQ weekly. Details of quality control and standardization of WS extract are provided as Supplementary File Number 1. The participants were jointly evaluated by an Ayurvedic and Modern Medicine physicians. The participants were tracked on a daily basis for adverse events (AE) using a specially designed mobile App (named as Covid Kavach). The primary efficacy measure was the incidence of symptomatic COVID-19 confirmed by a positive RT-PCR test for SARS-CoV-2. The study was powered at 80% with 95% confidence interval (CI), one-sided significance p<0.025.

Statistical analysis was carried out as per Wilson's recommended method using CIA software by BMJ group, London, 2002. An interim analysis of the first 160 participants, 80 in each arm, completing 8 weeks presented here was planned a-priori.

Participants in both the arms were well matched at the baseline characteristics (Table 1) . One participant in the WS arm and 3 in the HCQ arm contracted COVID-19 during the initial 8 J o u r n a l P r e -p r o o f weeks. Results indicate that WS was not inferior to HCQ and its efficacy was within the 15% non-inferiority margin set a-priori. The symptoms of confirmed COVID-19 were found to be 3.7% (95% CI 1.3 to 10.5%) in the HCQ and 1.3% (95% CI 0.02 to 6.7%) in the WS arm amongst the first 160 participants completing 8 weeks. The difference percentage between HCQ and WS among symptomatic and RT-PCR positive COVID-19 estimated as 2.4% (3.5 % to 9.3%) was within the pre-specified margin of 15%. 40 participants in the HCQ group and 26 participants in the WS group reported mild AE, however none required withdrawal from the study.

This study was planned when the vaccination option was not available and the need for chemoprophylaxis was obvious. Our intent was to explore a safer option to HCQ, which was standard care recommended by the ICMR. Our interim analysis suggests that Withania somnifera is not inferior to HCQ. Our results show non-inferiority for both symptomatic Covid 19 with RT-PCR and asymptomatic Covid 19 with RT-PCR and also for all RT-PCR positives. Given the long history of use of Ashwagandha in the community and available data on its efficacy and safety, it can be considered as a safer option to HCQ. Final report of this study is expected by end of August 2021.

All authors have made substantial contributions to this study. AC, BP and NS contributed to the conceptualization, methodology, and design of the study as well as its analysis and interpretation. ACRG include a team of clinical investigators and statistician. AC and NS contributed to coordination and acquisition of data. BP and AC prepared draft article and attended reviewers comments and revision.

The corresponding author is responsible for ensuring that the descriptions are accurate and agreed by all authors.

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial

Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science

ICMR Advisory on the use of Hydroxychloroquine as prophylaxis for SARS-CoV-2 infection dated

Ministry of AYUSH advisory page 8

Safety of Ashwagandha Root Extract: A Randomized, Placebo-Controlled, study in Healthy Volunteers

Exploratory study to evaluate tolerability, safety, and activity of Ashwagandha (Withania somnifera) in healthy volunteers

Safety assessment of Withania somnifera extract standardized for Withaferin A: Acute and sub-acute toxicity study

Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis

Selective Th1 up-regulating activity of Withania somnifera aqueous extract in an experimental system using flow cytometry

Withania somnifera (L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management

A Study of Ashwagandha in the Prophylaxis Against COVID-19 and its Benefits on General Health in High Risk Health Care Workers: A Randomized Controlled Comparison with Hydroxychloroquine Sulphate (HCQS)

Registration Number CTRI/2020/08/027163